ERT is the most common treatment for Fabry disease, and three different drugs are commercially available: Replagal (agalsidase alfa), Fabrazyme (agasidase beta) [8], and recently a next-generation ERT, Elfabrio (pegunigalsidase alfa). Here, GLA is linked to Fabry disease.